Lakewood-Amedex Biotherapeutics Inc. (LABT)
Nasdaq: LABT · Pharmaceutical Preparations · filing with the SEC since 2025
Who runs Lakewood-Amedex Biotherapeutics Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Cooper Kelvin
Chief Executive Officer. First filing May 2026, latest May 1, 2026, 0 filings in all.
Officers reporting now
3
of 5 people with a filing in the last fifteen months
Directors reporting now
2
5 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Cooper Kelvin | Chief Executive Officer | May 2026 | May 1, 2026 | none |
| Ceccacci Peter | Chief Financial Officer | May 2026 | May 1, 2026 | none |
| Balzer Thomas | Chief Medical Officer | May 2026 | May 1, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Tucker Joseph Edward | director | May 2026 | May 6, 2026 | none |
| Deroma Leonard James | director | May 2026 | May 1, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.